Showing results (181-190 of 410) with videos related to
Sort By:
Pageof 41
International Journal of Radiation Oncology, Biology, Physics|May 3, 2017
Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation TherapyAndrew Bang, Tyler J Wilhite, Luke R G Pike, et al.JCO Oncology Practice|May 14, 2020
Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic ColitisShilpa Grover, Alex B Ruan, Padmavathi Srivoleti, et al.Cancer Research|November 3, 2021
SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 AxisSatoru Yokoyama, Atsushi Takahashi, Ryota Kikuchi, et al.Journal for Immunotherapy of Cancer|March 10, 2022
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumorsOsama E Rahma, Kevin Tyan, Anita Giobbie-Hurder, et al.European Journal of Cancer (Oxford, England : 1990)|July 28, 2018
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancerStephen V Liu, D Ross Camidge, Scott N Gettinger, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid TumorsOmid Hamid, Dana B Cardin, F Stephen Hodi, et al.Oncolytic Virotherapy|August 12, 2016
Oncolytic virus therapy for cancerJoe Goldufsky, Shanthi Sivendran, Sara Harcharik, et al.Melanoma Research|December 25, 2012
Elevated rates of transaminitis during ipilimumab therapy for metastatic melanomaSebastian G Bernardo, Marina Moskalenko, Michael Pan, et al.Cancer Immunology Research|October 11, 2022
Hippo Signaling Pathway Regulates Cancer Cell-Intrinsic MHC-II ExpressionZexian Zeng, Shengqing Stan Gu, Nofal Ouardaoui, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 21, 2005
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901John D Roberts, Donna Niedzwiecki, William E Carson, et al.Pageof 41